Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCTR changes leaders

This article was originally published in The Tan Sheet

Executive Summary

William Slikker, Jr. is the new acting director of FDA's National Center for Toxicological Research, the agency announces Jan. 3. He replaces Don Casciano, who served as NCTR director for six years and will move to the private sector. Slikker, who is a member of the Teratology Society and the Society of Toxicology, is an adjunct professor in the the Department of Pharmacology & Toxicology at the University of Arkansas, and as associate editor of the journals NeuroToxicology and Toxicological Sciences. He most recently served as NCTR's Deputy Center Director for Research...

You may also be interested in...



Study Links Paclitaxel To Lower-Leg Amputations

New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.

Smith & Nephew Boosts ENT Portfolio, Acquires Tusker Medical

Smith & Nephew has acquired Tusker Medical for an undisclosed price. The acquisition comes just months after Tusker’s Tula system was approved by the FDA as a breakthrough device.

Topics

UsernamePublicRestriction

Register

PS098986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel